Today, AOD-9604 remains a topic of scientific interest, not as an approved therapy, but as a case study in how translational challenges can derail promising preclinical results
It remains to be determined whether boosting complimentary routes with exogenous substrates, such as citrate, or genetic/pharmacological interventions to increase ME1 or IDH1 levels and/or activity, is sufficient to counteract the excessive oxidative stress and hemolysis seen in G6PD def erythrocytes
The 500mcg oral dose in this formula is substantially lower than the doses used in pre-clinical injectable research
Learn more about TB-500 benefits and the BPC-157 vs TB-500 comparison
Importantly, there is no established contraindication to using weight loss injections in patients with MASLD or MASH
Testosterone replacement therapy introduces exogenous testosterone into your body, no longer relying on your bodys testicular production